<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> <z:hpo ids='HP_0000113'>polycystic kidney disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ARPKD</z:e>) gene, PKHD1, has been implicated in the genesis or growth of colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, as a high level of <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> was found in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> tissue </plain></SENT>
<SENT sid="1" pm="."><plain>To determine whether carriers of a single PKHD1 mutation are at increased risk of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp>, we assessed the prevalence of the commonest European mutation, T36M </plain></SENT>
<SENT sid="2" pm="."><plain>First, we assayed a European cohort of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ARPKD</z:e> patients and found T36M was responsible for 13.1% of mutations </plain></SENT>
<SENT sid="3" pm="."><plain>We then investigated two European cohorts with colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> versus two control cohorts of similar age and gender </plain></SENT>
<SENT sid="4" pm="."><plain>Screening for the most common PKHD1 mutation, T36M, we detected 15:3,603 (0.42%) controls versus 1:3,767 (0.027%) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> individuals, indicating that heterozygous PKHD1 mutations are not a risk factor and are protective (p=0.0002) </plain></SENT>
<SENT sid="5" pm="."><plain>We also show that the carriage rate for PKHD1 mutations in the European population is higher than previous accepted at 3.2% (1:31 genomes) </plain></SENT>
</text></document>